Portugal declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Archive — September 2024
Page 5 of 5 of this archive, newest first.
WWB declines, for the 18th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The United Kingdom pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Where the receptor is: a tissue-by-tissue account of tirzepatide’s reach
The same receptor population that produces the therapeutic effect produces the commonest adverse one.
Custody, condition and the temperature nobody logged
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Canada caps dulaglutide prescribing to 5 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The relabeller trading as Vantris Bio closes after 18 years
A proper account of an operation that existed, and of what closing it cost.